GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Price & Overview

OSL:GENTNO0010748866

Current stock price

42.4 NOK
+1.4 (+3.41%)
Last:

The current stock price of GENT.OL is 42.4 NOK. Today GENT.OL is up by 3.41%. In the past month the price increased by 11.58%. In the past year, price decreased by -15.2%.

GENT.OL Key Statistics

52-Week Range36.1 - 65.8
Current GENT.OL stock price positioned within its 52-week range.
1-Month Range37.4 - 43.4
Current GENT.OL stock price positioned within its 1-month range.
Market Cap
653.808M
P/E
49.88
Fwd P/E
15.87
EPS (TTM)
0.85
Dividend Yield
1.46%

GENT.OL Stock Performance

Today
+3.41%
1 Week
+11.29%
1 Month
+11.58%
3 Months
-26.90%
Longer-term
6 Months -20.00%
1 Year -15.20%
2 Years +3.92%
3 Years -12.58%
5 Years N/A
10 Years N/A

GENT.OL Stock Chart

GENTIAN DIAGNOSTICS ASA / GENT Daily stock chart

GENT.OL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to GENT.OL. When comparing the yearly performance of all stocks, GENT.OL is a bad performer in the overall market: 90.14% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GENT.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL. While GENT.OL has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GENT.OL Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

GENT.OL Forecast & Estimates

7 analysts have analysed GENT.OL and the average price target is 64.26 NOK. This implies a price increase of 51.56% is expected in the next year compared to the current price of 42.4.

For the next year, analysts expect an EPS growth of 204.65% and a revenue growth 19.34% for GENT.OL


Analysts
Analysts85.71
Price Target64.26 (51.56%)
EPS Next Y204.65%
Revenue Next Year19.34%

GENT.OL Groups

Sector & Classification

Index Membership

GENT.OL Financial Highlights

Over the last trailing twelve months GENT.OL reported a non-GAAP Earnings per Share(EPS) of 0.85. The EPS decreased by -70.75% compared to the year before.


Income Statements
Revenue(TTM)176.50M
Net Income(TTM)13.26M
Industry RankSector Rank
PM (TTM) 7.51%
ROA 5.13%
ROE 6.47%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-89.41%
Sales Q2Q%9.35%
EPS 1Y (TTM)-70.75%
Revenue 1Y (TTM)16.07%

GENT.OL Ownership

Ownership
Inst Owners39.64%
Shares15.42M
Float8.52M
Ins Owners2.68%
Short Float %N/A
Short RatioN/A

About GENT.OL

Company Profile

GENT logo image Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Company Info

IPO: 2016-12-14

GENTIAN DIAGNOSTICS ASA

Bjornasveien 5

Moss OSTFOLD NO

Employees: 64

GENT Company Website

GENT Investor Relations

Phone: 4799339905

GENTIAN DIAGNOSTICS ASA / GENT.OL FAQ

Can you describe the business of GENTIAN DIAGNOSTICS ASA?

Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.


Can you provide the latest stock price for GENTIAN DIAGNOSTICS ASA?

The current stock price of GENT.OL is 42.4 NOK. The price increased by 3.41% in the last trading session.


Does GENT stock pay dividends?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a dividend yield of 1.46%. The yearly dividend amount is currently 0.


What is the ChartMill rating of GENTIAN DIAGNOSTICS ASA stock?

GENT.OL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is GENTIAN DIAGNOSTICS ASA (GENT.OL) stock traded?

GENT.OL stock is listed on the Euronext Oslo exchange.


How is the valuation of GENTIAN DIAGNOSTICS ASA (GENT.OL) based on its PE ratio?

The PE ratio for GENTIAN DIAGNOSTICS ASA (GENT.OL) is 49.88. This is based on the reported non-GAAP earnings per share of 0.85 and the current share price of 42.4 NOK.